544417-40-5

Basic information

• Product Name: CAPADENOSON
• Synonyms: CAPADENOSON;2-Amino-6-[[[2-(4-chlorophenyl)-4-thiazolyl]methyl]thio]-4-[4-(2-hydroxyethoxy)phenyl]-3,5-pyridinedicarbonitrile;BAY 68-4986;Capadenoson, BAY 68-4986
• CAS NO: 544417-40-5
• Molecular Formula: C25H18ClN5O2S2
• Molecular Weight: 520.035
• Mol File: 544417-40-5.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 787.9±70.0 °C(Predicted)
• Appearance: /
• Density: 1.51
• Solubility: Soluble in DMSO
• PKA: 13.98±0.10(Predicted)
• CAS DataBase Reference: CAPADENOSON(CAS DataBase Reference)
• NIST Chemistry Reference: CAPADENOSON(544417-40-5)
• EPA Substance Registry System: CAPADENOSON(544417-40-5)

Safety Data

• Hazardous Substances Data: 544417-40-5(Hazardous Substances Data)

Usage

General Description

Capadenoson is a potent and selective A2A adenosine receptor agonist that has been developed as a potential alternative to adenosine for the diagnosis of coronary artery disease. It selectively activates the A2A adenosine receptor, leading to coronary vasodilation and an increase in coronary blood flow. Capadenoson has shown promising results in clinical trials, demonstrating its ability to induce hyperemic response and widen the coronary arteries without causing the side effects associated with adenosine, such as bronchoconstriction. Its favorable pharmacokinetic and pharmacodynamic profile makes it a promising candidate for use in cardiac stress testing and myocardial perfusion imaging for the diagnosis of coronary artery disease.

Upstream product

• 22042-73-5 4-(2-hydroxy-ethoxy)-benzaldehyde 
• 17969-22-1 4-chloromethyl-2-(4-chloro-phenyl)-thiazole 
• 112906-84-0 2-[4-(2-hydroxyethoxy)benzylidene]malononitrile 
• 7357-70-2 Cyanothioacetamide 
• 2521-24-6 4-chlorothiobenzamide 
• 544417-72-3 2-amino-4-[4-(2-hydroxyethoxy)phenyl]-6-sulfanylpyridine-3,5-dicarbonitrile 

Downstream Products

• 1239236-50-0 2-(4-(2-(((2-(4-chlorophenyl)-1,3-thiazol-4-yl)methyl)sulfanyl)-3,5-dicyano-6-(pyrrolidin-1-yl)pyridin-4-yl)phenoxy)ethyl N²,N⁶-bis(tert-butoxycarbonyl)-L-lysyl-L-alaninate 
• 1239234-60-6 2-((2-(4-chlorophenyl)-1,3-thiazol-4-ylmethyl)sulfanyl)-4-(4-(2-hydroxyethoxy)phenyl)-6-(piperidin-1-yl)pyridine-3,5-dicarbonitrile 
• 1239234-38-8 2-(((2-(4-chlorophenyl)-1,3-thiazol-4-yl)methyl)sulfanyl)-4-(4-(2-hydroxyethoxy)phenyl)-6-(methylamino)pyridine-3,5-dicarbonitrile 
• 1239234-50-4 2-(azetidin-1-yl)-6-((2-(4-chlorophenyl)-1,3-thiazol-4-ylmethyl)sulfanyl)-4-(4-(2-hydroxyethoxy)phenyl)pyridine-3,5-dicarbonitrile 
• 1239234-94-6 2-(((2-(4-chlorophenyl)-1,3-thiazol-4-yl)methyl)sulfanyl)-4-(4-(2-hydroxyethoxy)phenyl)-6-(3-methoxyazetidin-1-yl)pyridine-3,5-dicarbonitrile 
• 1239235-44-9 2-(4-(2-(((2-(4-chlorophenyl)-1,3-thiazol-4-yl)methyl)sulfanyl)-3,5-dicyano-6-(pyrrolidin-1-yl)pyridin-4-yl)phenoxy)ethyl β-alaninate trifluoroacetate 
• 1239235-17-6 2-(4-(2-(((2-(4-chlorophenyl)-1,3-thiazol-4-yl)methyl)sulfanyl)-3,5-dicyano-6-(pyrrolidin-1-yl)pyridin-4-yl)phenoxy)ethyl L-alaninate trifluoroacetate 
• 1110660-44-0 5-(2-{4-[2-amino-6-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}thio)-3,5-dicyanopyridin-4-yl]phenoxy}ethyl) 1-tert-butyl L-glutamate 

Relevant articles and documents

PROCESS FOR THE PREPARATION OF 2-{4-[2-({[2-(4-CHLOROPHENYL)-1,3-THIAZOL-4-YL]METHYL}SULFANYL)-3,5-DICYAN0-6-(PYRROLIDIN-1-YL)PYRIDIN-4-YL]PHENOXY}ETHYL-L-ALANYL-L-ALANINATE MONOHYDROCHLORIDE

The present application relates to a novel and improved process for preparing the compound 2-{4-[2-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulphanyl)-3,5-dicyano-6-(pyrrolidin-1-yl)pyridin-4-yl]phenoxy}ethyl-L-alanyl L-alaninate monohydrochloride of the formula (I) to novel precursors for its preparation, and to the preparation and use of crystal modification I of 2-{4-[2-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulphanyl)-3,5-dicyano-6-(pyrrolidin-1-yl)pyridin-4-yl]phenoxy}-ethyl-L-alanyl L-alaninate monohydrochloride of the formula (I).

SUBSTITUTED AZABICYCLIC COMPOUNDS AND THE USE THEREOF

The present application relates to novel substituted pyrrolopyridine, pyrazolopyridine and isoxazolopyridine derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, preferably for the treatment and/or prevention of cardiovascular disorders.

USE OF ADENOSINE A1 RECEPTOR AGONISTS FOR THE PROTECTION OF RENAL CELLS AGAINST TOXIC EFFECTS CAUSED BY AMINOGLYCOSIDES DURING TREATMENT OF INFECTIOUS DISEASES

The present invention refers to the use of adenosine Al receptor agonists for the protection of renal cells against toxic effects caused by aminoglycosides during treatment of infectious diseases in human.